Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 100 resultados

GRASSHOPPER: The GRASSHOPPER network Jumping forward from preclinical development of pediatric cancer drugs to c... Every year 16.000 children in Europe are diagnosed with cancer, and 2000 children (approximately 70 school classes) die from this illness. N...
2024-10-24 - 2028-11-30 | Financiado

PROCRYSTAL: Crystallisation towards efficient and sustainable biomanufacturing SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un HORIZON EUROPE: HORIZON-MSCA-2023-DN-01 "Downstream processing (DSP) of biopharmaceuticals is dominated by chromatographic steps which suffer from low throughput, poor scalability...
2024-07-10 - 2028-12-31 | Financiado

IDERHA: Integration of heterogeneous Data and Evidence towards Regulatory and HTA Acceptance SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage IDERHA will address the key obstacles to achieving appropriate access, sharing, use and reuse of lung cancer data, and thus enable enhanced...
2023-05-10 - 2028-03-31 | Financiado

SMiPAX4: Signalling of Minor Pocket Agonists at CXCR4 SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 The following project, SMiPAX4, conducted in the academic group of Jean-Philippe Herbeuval (Univeristy of Paris, France), is at the cross se...
2022-06-09 - 2025-02-28 | Financiado

EPND: European platform for neurodegenerative disorders SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage Alzheimer’s disease (AD) and Parkinson’s disease (PD) are common neurodegenerative conditions, posing a major societal burden. There is a la...
2021-10-25 - 2026-10-31 | Financiado

SCREEN4CARE: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technol... SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general populat...
2021-10-13 - 2026-09-30 | Financiado

FACILITATE: FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical eco... SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage FACILITATE is a project built on a patient-centered, data-driven, technological platform where an innovative data sharing and re-use process...
2021-10-11 - 2025-12-31 | Financiado

BIGPICTURE: Central Repository for Digital Pathology SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to crea...
2020-11-26 - 2027-01-31 | Financiado

ARDAT: Accelerating Research Development for Advanced Therapies SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado

H2O: H2O Health Outcomes Observatory SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Patients' outcomes and experience of health care can be improved through the systematic capture and use of information from their perspectiv...
2020-09-30 - 2025-09-30 | Financiado

PREMIER: Prioritisation and Risk Evaluation of Medicines in the EnviRonment SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage There are around 1900 active pharmaceutical ingredients (APIs) in use, yet the environmental risks of only a small proportion of these has b...
2020-06-24 - 2026-08-31 | Financiado

IDEA-FAST: Identifying Digital Endpoints to Assess FAtigue Sleep and acTivities in daily living in Neurodegene... SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-...
2019-12-18 - 2026-04-30 | Financiado

EU-PEARL: EU Patient cEntric clinicAl tRial pLatform SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company I...
2019-11-27 - 2023-04-30 | Financiado

imSAVAR: Immune Safety Avatar nonclinical mimicking of the immune system effects of immunomodulatory therapi... SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The vision of Immune Safety Avatar (imSAVAR) is to develop a platform for integrated nonclinical assessments of immunomodulatory therapy saf...
2019-11-18 - 2025-11-30 | Financiado

Trials@Home: Trials@Home Center of Excellence Remote Decentralised Clinical Trials SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage Clinical trials increase in size, complexity and costs. This is fuelled with the need to demonstrate effects in more complex therapeutic are...
2019-08-07 - 2025-11-30 | Financiado

ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado

IMMUcan: Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material...
2019-04-23 - 2025-08-31 | Financiado

CARDIATEAM: CARdiomyopathy in type 2 DIAbetes mellitus SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbi...
2019-04-11 - 2026-02-28 | Financiado

TransBioLine: Translational Safety Biomarker Pipeline TransBioLine Enabling development and implementation of n... SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Qualified biomarkers help to optimize drug development and patient safety, yet for the regulatory acceptance of safety biomarkers substantia...
2019-04-08 - 2025-01-31 | Financiado

MOBILISE-D: Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement SANOFIAVENTIS RECHERCHE DEVELOPPEMENT participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing...
2019-03-22 - 2024-06-30 | Financiado

SARD